KNTE - Kinnate Biopharma gets FDA fast track designation for its bile duct cancer treatment
- Kinnate Biopharma ( NASDAQ: KNTE ) on Tuesday said the U.S. Food and Drug Administration (FDA) had granted a fast track designation to its inhibitor KIN-3248 for the treatment of bile duct cancer.
- The FDA granted the designation to KIN-3248 for the treatment of patients with unresectable, locally advanced or metastatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 gene fusions or other alterations, who have received at least one prior systemic therapy.
- The FDA's Fast Track approval is a process designed to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need.
- Kinnate Biopharma ( KNTE ) stock earlier closed flat at $6.65.
For further details see:
Kinnate Biopharma gets FDA fast track designation for its bile duct cancer treatment